Mattia Bellan1, Marco Quaglia2, Alessandra Nerviani3, Daniele Mauro3, Myles Lewis3, Federica Goegan4, Antonello Gibbin5, Sara Pagani4, Livia Salmi4, Luca Molinari4, Luigi Mario Castello6, Gian Carlo Avanzi6, Vincenzo Cantaluppi2, Mario Pirisi5, Pier Paolo Sainaghi7, Costantino Pitzalis3. 1. Department of Translational Medicine, Università del Piemonte Orientale, Novara; Internal Medicine Division, Maggiore della Carità Hospital, Novara; IRCAD, Interdisciplinary Research Center of Autoimmune Diseases, Novara, Italy. bellanmattia@yahoo.it. 2. Department of Translational Medicine, Università del Piemonte Orientale, Novara; IRCAD, Interdisciplinary Research Center of Autoimmune Diseases, Novara; and Division of Nephrology and Renal Transplantation, Maggiore della Carità Hospital, Novara, Italy. 3. Centre for Experimental Medicine and Rheumatology, Barts and The London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, UK. 4. Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy. 5. Department of Translational Medicine, Università del Piemonte Orientale, Novara; and Internal Medicine Division, Maggiore della Carità Hospital, Novara, Italy. 6. Department of Translational Medicine, Università del Piemonte Orientale, Novara; and Emergency Medicine Department, Maggiore della Carità Hospital, Novara, Italy. 7. Department of Translational Medicine, Università del Piemonte Orientale, Novara; Internal Medicine Division, Maggiore della Carità Hospital, Novara; IRCAD, Interdisciplinary Research Center of Autoimmune Diseases, Novara, Italy.
Abstract
OBJECTIVES: Growth arrest-specific 6 (Gas6) and its receptors have been shown to play a crucial role in the homeostasis of the innate immune system by regulating apoptosis and inflammation. We aimed to verify whether an impairment of this system is associated with systemic lupus erythematosus (SLE) disease activity and with lupus nephritis (LN). METHODS: Plasma Gas6 and the soluble cleaved form of the receptors MerTK (sMer) and Axl (sAxl) concentrations were measured in n=59 SLE patients (n=44 with nephritis, 75%) and analysed in relationship to clinical and laboratory data. RESULTS: Patients with LN were characterised by higher Gas6 (19.0 ng/mL [16.8-24.5] vs. 16.5 ng/mL [13.89-18.91]; p=0.03) and sAxl plasma levels than those without LN (31.36 ng/mL [25.1-41.4] vs. 20.2 ng/mL [15.6-30.7]; p=0.03); conversely sMer plasma concentrations were similar between groups. All the three biomarkers studied were directly correlated to creatinine and daily proteinuria, being inversely related to creatinine clearance. 39 patients had a proteinuria level of <0.5 mg/day, 14 between 0.5 and 3.5 mg/day and 5 had ≥3.5 g/day; Gas6, sAxl and sMer plasma concentrations significantly increased for increasing degree of proteinuria (test for trend p=0.0002; p=0.02; p=0.009, respectively).These correlations were confirmed in multiple linear regression analysis models accounting for gender, age, disease duration and concomitant treatment. CONCLUSIONS: Plasma Gas6, sAxl and sMer concentrations are associated with the severity of LN in patients affected by SLE. The excess cleavage of TAM receptors might contribute to LN pathogenesis.
OBJECTIVES: Growth arrest-specific 6 (Gas6) and its receptors have been shown to play a crucial role in the homeostasis of the innate immune system by regulating apoptosis and inflammation. We aimed to verify whether an impairment of this system is associated with systemic lupus erythematosus (SLE) disease activity and with lupus nephritis (LN). METHODS: Plasma Gas6 and the soluble cleaved form of the receptors MerTK (sMer) and Axl (sAxl) concentrations were measured in n=59 SLE patients (n=44 with nephritis, 75%) and analysed in relationship to clinical and laboratory data. RESULTS: Patients with LN were characterised by higher Gas6 (19.0 ng/mL [16.8-24.5] vs. 16.5 ng/mL [13.89-18.91]; p=0.03) and sAxl plasma levels than those without LN (31.36 ng/mL [25.1-41.4] vs. 20.2 ng/mL [15.6-30.7]; p=0.03); conversely sMer plasma concentrations were similar between groups. All the three biomarkers studied were directly correlated to creatinine and daily proteinuria, being inversely related to creatinine clearance. 39 patients had a proteinuria level of <0.5 mg/day, 14 between 0.5 and 3.5 mg/day and 5 had ≥3.5 g/day; Gas6, sAxl and sMer plasma concentrations significantly increased for increasing degree of proteinuria (test for trend p=0.0002; p=0.02; p=0.009, respectively).These correlations were confirmed in multiple linear regression analysis models accounting for gender, age, disease duration and concomitant treatment. CONCLUSIONS: Plasma Gas6, sAxl and sMer concentrations are associated with the severity of LN in patients affected by SLE. The excess cleavage of TAM receptors might contribute to LN pathogenesis.
Authors: Richard Witas; Astrid Rasmussen; Robert H Scofield; Lida Radfar; Donald U Stone; Kiely Grundahl; David Lewis; Kathy L Sivils; Christopher J Lessard; A Darise Farris; Cuong Q Nguyen Journal: Int J Mol Sci Date: 2021-09-08 Impact factor: 6.208
Authors: Lichchavi D Rajasinghe; Melissa A Bates; Abby D Benninghoff; Kathryn A Wierenga; Jack R Harkema; James J Pestka Journal: Front Immunol Date: 2022-01-21 Impact factor: 7.561
Authors: Juliana de Andrade Rebouças Guimarães; Silvania da Conceição Furtado; Ana Cyra Dos Santos Lucas; Bruno Mori; José Fernando Marques Barcellos Journal: PLoS One Date: 2022-10-10 Impact factor: 3.752